POM-V Prescription Required Companion Animal

Telmitraxx 4 mg/ml Oral Solution for Cats

Active ingredient: Telmisartan

Form

Liquid

Species

Cats

Manufacturer

Alfasan Nederland B.V.

VMD MA No.

36408/5016

What it's used for

Reduction of proteinuria associated with chronic kidney disease (CKD).

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Telmisartan

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Telmitraxx 4 mg/ml Oral Solution for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Reduction of proteinuria associated with chronic kidney disease (CKD).

Do not use during pregnancy or lactation (see also section 4.7).
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Cats:
Rare
(1 to 10 animals / 10,000
animals treated):
Gastrointestinal signs (regurgitation
, vomiting,
diarrhoea)
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Elevated liver enzymes²
Decreased red blood cell counts (see section 3.5).
Mild and intermittent
² Values normalised within a few days following cessation of therapy.
Reporting adverse events is important. It allows continuous safety monitoring of
a veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder <or its local

Issued: July 2023
AN: 02993/2021
representative> or the national competent authority via the national reporting
system. See the package leaflet for respective contact details.

None.

i). Special precautions for use in animals
The safety and efficacy of telmisartan has not been tested in cats under the age
of 6 months.

Issued: July 2023
AN: 02993/2021
It is good clinical practice to monitor the blood pressure of cats receiving
telmisartan which are under anaesthesia.
Due to the mode of action of the veterinary medicinal product, transient
hypotension may occur. Symptomatic treatment, e.g. fluid therapy, should be
provided in case of any clinical signs of hypotension.
As known from substances acting on the Renin-Angiotensin-Aldosterone
System (RAAS), a slight decrease in red blood cell count may occur. Red blood
cell count should be monitored during therapy. Substances acting on the RAAS
may lead to a reduction in glomerular filtration rate and worsening renal function
in cats with severe kidney disease. The safety and efficacy of telmisartan in
such patients has not been investigated. When using this veterinary medicinal
product in cats with severe kidney disease, it is advisable to monitor renal
function (plasma creatinine concentration).
ii). Special precautions to be take by the person administering the veterinary
medicinal product to animals
This product may cause adverse effects, such as headache, dizziness or
hypotension. Avoid oral ingestion by children. In case of accidental ingestion,
seek medical advice immediately and show the package leaflet or the label to
the physician.
This product may cause eye-irritation. Avoid eye contact. In case of accidental
eye contact, rinse eyes with water.
Pregnant women should take special care to avoid contact with the veterinary
medicinal product because substances acting on the RAAS, such as
Angiotensin Receptor Blockers (ARBs) and ACE inhibitors (ACEis), have been
found to affect the unborn child during pregnancy in humans.
Telmisartan may cause allergic reactions. People with hypersensitivity to
telmisartan or other sartans/ARBs should avoid contact with the veterinary
medicinal product.
Wash hands after use.
iii). Other precautions
Not applicable

During concomitant therapy with amlodipine at the recommended dose, no
clinical evidence of hypotension was observed.
No drug-drug interactions are known from available data in cats with CKD for
the use of telmisartan and other medicinal products that interfere with RAAS
(such as ARBs or ACEis). The combination of agents targeting the RAAS may
alter renal function.

Store below 30°C
Store in the original container in order to protect from light.

Not applicable.

Issued: July 2023
AN: 02993/2021
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.